



KYTTARO

Pioneering Cardiovascular Therapeutics

A Cambridge Science Affiliate

Kyttaro Limited
BioEscalator
Innovation Building
Old Road Campus, Oxford
OX3 7FZ
www.kyttaro.com

Corporate Press Release

Wednesday, February 23, 2022

Kyttaro announces the appointment of world-renowned medicinal chemist John E. Macor, Ph.D., the 2020 recipient of the IUPAC-Richter Prize in Medicinal Chemistry, as co-chair of the company's Scientific Advisory Board

Dr. Macor, an inductee to the ACS Division of Medicinal Chemistry Hall of Fame, is the previous Global Head of Integrated Drug Discovery at Sanofi where he led a team of over 500 drug discovery scientists in eight divisions across multiple therapeutic classes

Oxford, U.K. and Cambridge, Massachusetts, February 23, 2022

Kyttaro continues to build out its scientific leadership team with the addition of John E. Macor, a small molecule expert and highly innovative scientist, to the company's Scientific Advisory Board, where he will serve as a co-chair, along with current co-chair Dr. Alan Ashworth, President of the of the UCSF Helen Diller Family Comprehensive Cancer Center.

Dr. Macor has enjoyed an extraordinary 35-year drug discovery career in neuroscience, cardiovascular, immunology, oncology, rare disease and infectious diseases at some of the world's leading pharmaceutical companies, Sanofi, Bristol Myers Squibb, Astra Arcus, and Pfizer. He has advanced more than fourteen compounds into human clinical trials and twenty-five compounds into pre-IND development during his illustrious career. Dr. Macor is the co-inventor of two FDA approved drugs, Relpax[®] (Eletriptan) and Nurtec[®] ODT (Rimegepant), an oral CGRP receptor antagonist for the treatment of migraine approved in February 2020. Since its launch two years ago, Nurtec[®] ODT has delivered much needed treatment to more than 1 million migraine patients and is on pace to achieve blockbuster status.

He is the author or a co-author on more than 200 peer-reviewed publications and the inventor on 135 issued U.S. patents. Dr. Macor earned his B.S. degree summa cum laude from the University of Notre Dame and his Ph.D. in organic chemistry from Princeton University.

John Macor said:

I am very excited to join Kyttaro as a co-chair for their SAB and its innovative portfolio as part of the next steps in my career.



KYTTARO

Pioneering Cardiovascular Therapeutics

A Cambridge Science Affiliate

Kyttaro Limited
BioEscalator
Innovation Building
Old Road Campus, Oxford
OX3 7FZ
www.kyttaro.com

Douglas Eby, Founder and Chief Executive Officer of Kyttaro, commented:

Kyttaro's ability to achieve its goal of helping patients who are suffering from disease by developing and commercializing novel therapeutics has become greatly enhanced with the addition of John to our team. His four-decade track record of success in drug discovery and development puts him in an exclusive club and the Kyttaro team is looking forward to receiving his valuable counsel and guidance. I am extremely grateful for the opportunity to work with John.

ABOUT KYTTARO

Kyttaro, an affiliate of Cambridge Science, is a United Kingdom headquartered clinical stage biosciences company, with offices in Kendall Square, Cambridge, Massachusetts, that is developing innovative therapeutics to treat hypertriglyceridemia, atherosclerotic cardiovascular disease and inflammatory and neurogastroenterology conditions.

For more information please contact:

Matthias Thurner, DPhil – SVP of Scientific Strategy mthurner@kyttaro.com
Arkadiy Chapko, MBA – Chief Financial Officer achapko@kyttaro.com